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West Africa – consisting of countries
such as Guinea, Liberia, Sierra Leone, and
Nigeria – is the westernmost region of the
African continent. Afflicted by widespread
poverty and political instability,West Africa
is one of the poorest regions in the world –
Liberia, Sierra Leone, and Guinea are
respectively ranked 174, 177, and178 out
of 187 countries on the United Nations
Development Program Human Develop-
ment Index (1). This region is in the news
of late, not because of the poverty per se
but due to one of its repercussions – its
impact on health. The West African coun-
try Guinea encountered a new epidemic
in March this year, which subsequently
encroached upon Liberia and Sierra Leone
and turned out to be an unprecedented
event in health sector of West Africa (2).
Ebola, a viral disease characterized by fever,
diarrhea, vomiting, and hemorrhage (3),
entered this region and started a disease
outbreak. So great has been the havoc of
this outbreak that 3685 cases and 1841
deaths have been reported as of 31 August
2014 (4). These are mere tangible effects of
the disease; it has stirred a monumental fear
in people around the globe, to say nothing
of people from these suffering countries.
Ebola virus is a filamentous virus, five
species of which have been identified; three
of these species have been responsible for
outbreaks in sub-Saharan African coun-
tries such as Sudan, Republic of Congo,
Gabon, and Uganda (3). Zaire ebolavirus,
also known as EBOV, is responsible for
the ongoing Ebola hemorrhagic fever out-
break; its clinical manifestations closely
resembles Marburg viral disease, a disease
native to Africa and caused by another
filovirus named Marburg virus (3). Its first
appearance – and detection – harkens back
to 1976, when it was observed during a
hemorrhagic fever outbreak in southern
Sudan and northern Zaire (5). Ebola viral
disease, a zoonotic disease, has since been
observed intermittently in different regions
of Central Africa (6), but none of those
has wreaked damage as monumental as the
ongoing outbreak.
The current Ebola viral disease outbreak
is turning out to be an insidious threat
to the public health of West Africa – and
by extension, to global health. Widespread
poverty and corruption, underdeveloped
health care systems, and lack of proper edu-
cation in these West African countries have
been a significant factor in the eruption
and spread of this disease. Due to these
and other reasons, most of these African
nations have been unable to stem the out-
break. One exception to this has been Nige-
ria, which has been able to control this
epidemic (7). A lot of effort has been
put into reversing this epidemic, primar-
ily from developed nations and interna-
tional organizations. The outbreak, how-
ever, still remains to be brought under con-
trol. This has raised issues regarding our
health systems, state-of-the-art research
facilities, and regulatory laws pertaining to
health. This outbreak stands out as a health
emergency and also displays some of our
collective limitations.
IMPLICATIONS OF THE OUTBREAK
The ongoing outbreak has raised con-
cerns about the flexibility and timeliness
of research and development of drugs
and vaccines. We have come a long way
in regards to technological development
and innovation, especially in the last few
decades. Yet, an efficacious treatment or
prevention for Ebola could not be made
available in the hour of need, despite
vigorous research efforts. Existence of
numerous strains of a single virus species
and their continued mutation – as is the
case with the current Ebola infection (8) –
often stymies the research for anti-viral
drugs. This is similar to the case with
antibiotics, where bacterial resistance is a
chief concern (9). Bacterial and viral dis-
eases benefit from the ever-evolving genetic
makeup of their agents, which are capable
of rapidly rendering a treatment ineffec-
tive. Despite advances in genome sequenc-
ing (10), the current Ebola outbreak has
reinforced the notion that research in ther-
apeutics, especially for viral and bacterial
infections, has a long way to go.
Diseases such as Ebola fall in the cat-
egory of rare diseases, which do not con-
tribute significantly to disease burden in
the affected areas, let alone globally. That
Ebola, first identified in 1976, has occurred
sporadically in the last three decades does
not encourage the discovery of drugs
for the disease. Far fewer people have
been affected by Ebola as compared to
some global diseases such as tuberculo-
sis or malaria (11). The lack of incen-
tives for treatments of such intermittently
occurring diseases, rather than the inabil-
ity of pharmaceutical industries, has been
pointed out to be the reason for non-
existence of efficacious treatments for the
disease (12). There is not much mone-
tary benefit for pharmaceutical industries
in this line of research. As a result, phar-
maceutical industries are not foraying into
research for therapeutics for such rare dis-
eases (11, 12). This issue has been raised
earlier with respect to the unwillingness
of pharma industries to get involved in
antibiotics research (13). The culpability
of pharma industries, however, is not as
black and white as it is claimed to be.
Innumerable rare diseases are prevalent
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throughout the world, and taking initia-
tives for developing drugs for each of
these diseases is not always possible or
financially advisable. On the other hand,
neglecting these diseases could lead to seri-
ous consequences, as indicated by cur-
rent Ebola outbreak. The current outbreak
has fueled the criticism of pharmaceu-
tical industries for being market-driven.
More significantly, it has highlighted the
predicament of health and drug research
domain.
The economic and political implica-
tions of the current outbreak have grabbed
more attention. The fact that the outbreak
has occurred in West Africa and that these
regions possess threadbare socio-economic
framework, highlights the relationship of
weak economic and political systems with
the ongoing epidemic. Guinea, Liberia, and
Sierra Leone – the epicenter of the cur-
rent Ebola outbreak – were at the receiv-
ing end of civil conflicts (in Liberia and
Sierra Leone) and an inefficient govern-
ment (in Guinea) for decades. This has left
these countries with debilitated infrastruc-
tures, health sector being no exception (1,
2). Political upheavals indeed disrupt the
very fabric that holds a country together,
and this disruption has spilled over to
the economic and health sectors in these
African countries. That Nigeria, a com-
paratively developed and more stable West
African country, has been able to check
the spread of Ebola bolsters the impor-
tance of political and economic stability
(7). Moreover, poverty is deep-rooted, and
resources are limited in these countries.
In fact, poverty has been regarded as the
single most important factor for the unbri-
dled nature of this outbreak (14). Admit-
tedly, the current Ebola outbreak calls for
a closer look at the socio-economic and
political background of countries fraught
with epidemics.
This outbreak has also brought to
the fore the significance of education,
environmental factors, and cultural fac-
tors in a disease outburst. Ebola, being
a zoonotic disease, has afflicted humans
owing to greater reliance of people on ani-
mal products, predominantly meat, and
repeated visits to forests and mines for
wood and minerals (1). Traditional prac-
tices in disease-affected West African coun-
tries are regarded to be health hazard-
prone (bathing of corpses by hand before
burial, for instance), which have been
instrumental in perpetuating the outbreak
(2). Further, the lack of proper education
in the people and their unwillingness to
accept the existence itself of the disease
have been major threats in checking its
spread.
The current outbreak has underscored
a certain flaw in handling ethical issues at
the time of emergency. The ethical require-
ments surrounding the approval of new
drugs have come under scrutiny, cour-
tesy of the current outbreak. Drugs that
have shown positive effects against Ebola
virus in laboratories and on animal sub-
jects are waiting for their use in Ebola
patients – this long wait has resulted from
rigorous requirements of safety and effi-
cacy testing in human subjects. One such
product is ZMapp – a combination of
three monoclonal antibodies – which has
shown successful abortion of Ebola infec-
tion in non-human primates (monkeys)
(15). It has been successfully employed in
the treatment of two United States health-
care workers, the therapy being driven by
compassionate use rather than substan-
tial evidence – efficacy and safety testing
have not been carried out on human sub-
jects (16). With limited data about effi-
cacy and toxicity of the therapy, its effect
on treating Ebola infection has not been
well-established. This raises an important
question about design of clinical trials and
its modification based on urgent needs.
Changes in the current lengthy procedure
for drug approval to allow for rapid test-
ing and acceptance of therapies, especially
in critical times, are considered to be a
remedy for such bottlenecks (17). Clearly,
the status quo of drug testing, approv-
ing, and regulating does not hold good
in certain cases of disease outburst, thus
warranting a tweaking of presently estab-
lished guidelines. The current outbreak has
been instrumental in underlining the sig-
nificance of the regulatory aspect of new
therapies.
PITFALLS
The ongoing Ebola outbreak raises some
serious questions, the answers to which
could be harrowing. What if this outbreak
or such types of viral outbreaks happen not
to be rare events? What if Ebola and Mar-
burg are just the tip of the viral iceberg
and plenty more are bracing themselves
for human infection? Although these ques-
tions sound cynical, it is high time that
these questions were asked. In fact, con-
cerns were raised earlier about the negli-
gence of Ebola outbreaks in the past, with
warnings that a bigger outbreak could arise
(18). We are not well-informed about the
entire arsenal of microbes in nature, as
this outburst of a zoonotic disease demon-
strates. Moreover, urbanization and glob-
alization are in full swing, and have forced
people to exploit the nature for sustenance
(18). With greater delving into the nature
for resources, there is enhanced possibil-
ity of transmission of newer and possibly
more threatening diseases. We have already
been grappling with HIV, which is a global
health issue at the moment. This outbreak
could well point to a future marred with
such other health threats, if serious delib-
erations are not performed by professionals
of different backgrounds, including econ-
omists, political leaders, and public health
experts.
The current Ebola spread, which could
have been limited to few people and to
a small area through public health mea-
sures alone, has snowballed into wide-
spread havoc. Non-pharmaceutical inter-
ventions have been shown to be effective
in curtailing the spread of a disease, as
observed with Influenza pandemic in the
United States (19). In order to implement
public health measures, however, the health
sector needs to be strong, which is not the
case in African countries. Diseases such
as Ebola exist at the intersection of envi-
ronmental, socio-economic, cultural, and
public health systems of a society. Eruption
of such a disease indicates serious flaws in
more than one system, which is evident in
the ongoing Ebola outbreak.
In conclusion, a consensual effort on the
part of local and international health bod-
ies, pharmaceutical industries, and pub-
lic health experts may, hopefully, end the
current outbreak soon. In doing so, the
inherent message of this outbreak needs
to be assimilated as well, and measures
ought to be taken to prevent future out-
breaks. Surely, we do not want to make an
HIV/AIDS, a global health threat, out of
other such infectious diseases.
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